NOC Stock Recent News

FALLS CHURCH, Va., June 19, 2025 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) announced today that its second quarter 2025 financial results will be posted on its investor relations website on Tuesday, July 22, 2025. Prior to the market opening, the company will issue an advisory release notifying the public of the availability of the complete and full text earnings release on the company's website at http://investor.northropgrumman.com.

It's good to have friends (in space).

Travel and leisure stocks bore the brunt of investor anxiety on Friday after Israel launched airstrikes on Iranian targets, stoking fears of an escalating conflict in the Middle East. The strikes, aimed at crippling Iran's nuclear infrastructure, rattled global markets and sent oil prices surging, sparking a classic flight to safety.

Defense stocks will be in the spotlight on Friday and in the coming days as investors focus on the ongoing crisis in the Middle East where Israel attacked Iran's nuclear sites.

Several war stocks surged today following news of the Israeli strike on Tehran, Iran.

The world is getting more chaotic, and it makes sense to add some high-quality defense contractors to your portfolio as a hedge. Lockheed Martin and Northrop Grumman are two top defense contractors. Which is the 'better buy'? While LMT is larger and produces higher profile jet fighters and weapons systems, we prefer NOC's position in the military stack.

Raytheon advances NGSRI development with continued testing TUCSON, Ariz. , June 5, 2025 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, and Northrop Grumman (NYSE: NOC) announced four successful tests of flight-ready Highly Loaded Grain (HLG) solid rocket motors for the U.S. Army's Next-Generation Short-Range Interceptor (NGSRI).

Dividend growth investing prioritizes stocks with consistent payout increases, offering rising income and inflation protection for long-term stability.

High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delivers a 3.5% yield with double-digit EPS growth potential.

Northrop Grumman's unique position as a system architect for US strategic defense programs ensures stable, predictable revenue from government contracts. My DCF valuation model, using multiple methods, yields a fair value of $550 per share—about a 16% potential upside—supporting a Buy rating for NOC. The company's robust free cash flow, consistent dividend growth, and aggressive buybacks offer reliable shareholder returns.